Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished ... a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 2.61% to £19.64 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) jumped on Thursday after the company raised its full-year guidance ...

Hikma Pharmaceuticals Plc (HKMPF) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0 ...

Hikma Pharmaceuticals ... pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...